摘要
目的探讨半夏泻心汤合并帕罗西汀治疗躯体形式障碍女性患者的疗效及安全性。方法将66例躯体形式障碍女性患者随机分为研究组(32例)和对照组(34例),研究组患者接受半夏泻心汤合并帕罗西汀系统治疗,对照组患者接受帕罗西汀系统治疗,共治疗6周。所有入组患者在基线及治疗后第1、2、4、6周末应用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)和治疗中需处理的不良反应症状量表(TESS)评估疗效和安全性。结果治疗后第2周末起,研究组患者HAMD评分较基线时显著降低(P<0.05),而在治疗后第4周末起,对照组患者的HAMD评分较基线时才有显著降低(P<0.01)。治疗后第2周末起,研究组患者HAMD评分显著低于对照组(P<0.01)。治疗后第2周末起,两组患者的HAMA评分均较基线时显著降低(P<0.05)。治疗后第1周末,研究组患者的TESS评分高于对照组(P<0.05),其他时间点两组间TESS评分无显著性差异(P>0.05)。经6周治疗研究组显效率显著高于对照组(81.25%∶52.94%,χ2=8.47,P<0.05)。结论半夏泻心汤合并帕罗西汀可有效治疗躯体形式障碍女性患者,起效更快,安全性较高。
Objective To explore the efficacy and safety of Banxia-xiexin decoction combined with paroxetine in treatment of female patients with somatoform disorder.Methods 66 female patients with somatization disoder were randomized into study group （32 cases） treated with Banxia-xiexin decoction combined with paroxetine and control group （34 cases） treated with paroxetine monotherapy for 6 weeks.All patients were assessed with Hamilton Depression Scale （HAMD）,Hamilton Anxiety Scale （HAMA） and Treatment Emergent Symptom Scale （TESS） at baseline and at the 1st,2nd,4th,6th weekend of the treatment to evaluate the efficacy and side effects.Results Compared with baseline,score of HAMD in study group decreased significantly from the the 2nd weekend of the treatment （P ＜ 0.05）,while in control group the significant decrease appeared from the 4th weekend （P ＜0.01）.Scores of HAMD in study group were significantly lower than those in control group from the 2nd weekend of the treatment （P ＜0.05）.Scores of HAMA in both groups decreased significantly from the end of the 2nd week of the treatment （P ＜ 0.01）.Score of TESS was significantly higher in study group than that in control group at the 1 st weekend （P ＜ 0.05）,while the significance disappeared at other interview-points （P ＞ 0.05）.The response rate in study group was significantly higher than that in control group at the end of the 6-week treatment （81.25％ vs.52.94％,x2 =8.47,P ＜ 0.05）.Conclusion Banxia-xiexin decoction combined with paroxetine has rapid action and good safety in the treatment of femal patients with somatoform disorder.
出处
《精神医学杂志》
2014年第2期128-130,共3页
Journal of Psychiatry
